BioDelivery Sciences International (NASDAQ:BDSI) released its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.02, Fidelity Earnings reports. BioDelivery Sciences International had a negative return on equity of 388.58% and a negative net margin of 122.75%. The firm had revenue of $12.18 million for the quarter, compared to the consensus estimate of $12.44 million.
BioDelivery Sciences International traded down $0.03, hitting $2.88, during trading hours on Friday, Marketbeat reports. 404,567 shares of the stock traded hands, compared to its average volume of 438,345. The company has a debt-to-equity ratio of 35.82, a quick ratio of 1.13 and a current ratio of 1.40. The stock has a market cap of $172.12 million, a price-to-earnings ratio of -7.31 and a beta of 0.38. BioDelivery Sciences International has a one year low of $1.70 and a one year high of $3.42.
A number of research analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of BioDelivery Sciences International in a report on Friday, July 6th. Cantor Fitzgerald restated a “buy” rating and set a $4.50 price target on shares of BioDelivery Sciences International in a report on Thursday. Zacks Investment Research downgraded BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Tuesday, July 24th. Finally, ValuEngine upgraded BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $4.13.
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Recommended Story: Price to Earnings Ratio (PE)
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.